Concepedia

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

Sergio Bracarda, Roberto Iacovelli, Luca Boni, Mimma Rizzo, Lisa Derosa, Marta Rossi, Luca Galli, Giuseppe Procopio, Michele Sisani, Flavia Longo,

Annals of Oncology · 2015 · 105 citations · 13 references

DOIFull text

Open access

Concepts

References

13

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 5.8K citations · Full text

, , +14

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak et al. · Journal of Clinical Oncology · 2009 · 2.2K citations

, , +13

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan et al. · Journal of Clinical Oncology · 2009 · 2.1K citations · Full text

, , +17

Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, Brian I. Rini, Ronald M. Bukowski et al. · JAMA · 2006 · 1.2K citations

, , +17

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Sandrine Faivre, Catherine Delbaldo, Karina Vera et al. · Journal of Clinical Oncology · 2005 · 1.2K citations · Full text

, , +17